The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2021 | Evaluating the LIPI for first line immunotherapy in NSCLC
Laura Mezquita, Hospital Clinic Barcelona, Barcelona, Spain, discusses an analysis of the applicability of the Lung Immune Prognostic Index (LIPI) to first line treatment of advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICI). The association of the LIPI with immunotherapy outcomes in the pretreated NSCLC setting has been previously established. Patients treated with ICI monotherapy, ICI combined with CTLA4-inhibitor, or ICI plus chemotherapy were identified for this retrospective analysis. Over 900 patients were enrolled and their LIPI scores were calculated and grouped. The results showed that LIPI scores were correlated with outcomes. The LIPI poor subgroup had a significantly worse overall survival than other subgroups and progression-free survival was correlated with LIPI scores in the overall study population. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.
Disclosures
Research grants/funding: Bristol Myers Squibb, Boehringer Ingelheim, Amgen
Advisory/Consultancy: Roche Diagnostics, Takeda
Honoraria: Bristol Myers Squibb, Tecnofarma, Roche
Travel/Accommodation/Expenses: Roche
Non-remunerated activity: AstraZeneca
